Dose response of MTLn3 cells to serial dilutions of arsenic trioxide and ionizing radiation

Dose-Response

Volumn 11, Issue 1, 2013, Pages 29-40

  Raja, Waseem Khan ^a   Satti, Jahangir ^b   Liu, Gang ^b   Castracane, James ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Cancer cells; Hormesis; Ionizing radiation

Indexed keywords

ARSENIC TRIOXIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DNA DETERMINATION; DOSIMETRY; DRUG RESISTANCE; HORMESIS; IONIZING RADIATION; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; MITOCHONDRION; MONOTHERAPY; MTLN3 CELL; NONHUMAN; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION EXPOSURE; RAT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874064732     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.11-025.Raja     Document Type: Article

References (31)

1. Azim HA, Jr., de Azambuja E, Colozza M, Bines J and Piccart MJ. 2011. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol.
2. Bacquart T, Deves G and Ortega R. 2010. Direct speciation analysis of arsenic in sub-cellular compartments using micro-X-ray absorption spectroscopy. Environ Res 110(5): 413-416.
3. Belz RG, Cedergreen N and Sorensen H. 2008. Hormesis in mixtures-can it be predicted? Sci Total Environ 404(1): 77-87.
4. Chiu HW, Lin JH, Chen YA, Ho SY and Wang YJ. 2010. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy 6(3): 353-365.
5. Cui X, Kobayashi Y, Akashi M and Okayasu R. 2008. Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. Curr Med Chem 15(22): 2293-2304.
6. Cutuli B, Kanoun S, Tunon De Lara C, Baron M, Livi L, Levy C, Cohen-Solal-Lenir C, Lesur A, Kerbrat P, Provencio M, Gonzague-Casabianca L, Mege A, Lemanski C, Delva C, Lancrenon S and Velten M. 2011. Breast cancer occurred after Hodgkin's disease: Clinico-pathological features, treatments and outcome: Analysis of 214 cases. Crit Rev Oncol Hematol.
7. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S and Kerbel RS. 2011. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1): 40-48.
8. Emmenegger U, Francia G, Shaked Y and Kerbel RS. 2010. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res 180: 165-183.
9. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R and Bocci G. 2010. Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? Drugs Aging 27(9): 689-696.
10. Ge HL, Liu SS, Zhu XW, Liu HL and Wang LJ. 2010. Predicting Hormetic Effects of Ionic Liquid Mixtures on Luciferase Activity Using the Concentration Addition Model. Environ Sci Technol.
11. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN. 2007. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
12. Goswami S, Wang W, Wyckoff JB and Condeelis JS. 2004. Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. Cancer Res 64(21): 7664-7667.
13. Juhasz B, Mukherjee S and Das DK. 2010. Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol 15(4): e134-138.
14. Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, Chung HY, Mattson MP and Lee J. 2008. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 283(21): 14497-14505.
15. Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH and Polverini PJ. 2008. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol Cancer Ther 7(7): 2060-2069.
16. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V and Pandha H. 2007. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177(6): 2136-2140; discussion 2140.
17. Massaccesi M, Forni F, Spagnuolo P, Macchia G, Mignogna S, De Ninno M, Cellini N, Giardina B, Carbone A and Morganti AG. 2010. Multiple tumor marker elevation in androgen ablationrefractory prostate cancer with long-term response to metronomic chemotherapy: a case report. Int J Biol Markers 25(4): 243-247.
18. Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR and Mendenhall NP. 2008. Re-irradiation of head and neck carcinoma. Am J Clin Oncol 31(4): 393-398.
19. Moskalev AA, Plyusnina EN and Shaposhnikov MV. 2011. Radiation hormesis and radioadaptive response in Drosophila melanogaster flies with different genetic backgrounds: the role of cellular stress-resistance mechanisms. Biogerontology.
20. Ning S and Knox SJ. 2004. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys 60(1): 197-203.
21. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS and Link MP. 2010. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 28(7): 1232-1239.
22. Platanias LC. 2009. Biological responses to arsenic compounds. J Biol Chem 284(28): 18583-18587.
23. Raja WK, Gligorijevic B, Wyckoff J, Condeelis JS and Castracane J. 2010. A new chemotaxis device for cell migration studies. Integr Biol (Camb) 2(11/12): 696-706.
24. Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K and Sparano JA. 2011. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol.
25. Raof NA, Raja WK, Castracane J and Xie Y. 2011. Bioengineering embryonic stem cell microenvironments for exploring inhibitory effects on metastatic breast cancer cells. Biomaterials 32(17): 4130-4139.
26. Satti J. 2009. The emerging low-dose therapy for advanced cancers. Dose Response 7(3): 208-220.
27. Senkus E and Jassem J. 2010. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 37(4): 300-311.
28. Thoenes L, Hoehn M, Kashirin R, Ogris M, Arnold GJ, Wagner E and Guenther M. 2010. In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J Proteomics 73(7): 1342-1354.
29. Tomuleasa C, Soritau O, Kacso G, Fischer-Fodor E, Cocis A, Ioani H, Timis T, Petrescu M, Cernea D, Virag P, Irimie A and Florian IS. 2010. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. J BUON 15(4): 758-762.
30. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J and Segall JE. 2006. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66(1): 192-197.
31. Zander AR and Kroger N. 2005. High-dose therapy for breast cancer a case of suspended animation. Acta Haematol 114(4): 248-254.